- Home
- » Tags
- » Entrectinib
Top View
- Update on Molecular Pathology and Role of Liquid Biopsy in Nonsmall Cell Lung Cancer
- GO40782 28Aug2018.Pdf
- NTRK Gene Amplification in Patients with Metastatic Cancer
- Malignant, Locally Aggressive Connective Tissue Tumours
- Entrectinib) FACT SHEET
- Application Number
- Entrectinib (Rozlytrek®) EOCCO POLICY
- Tolerance Profile and Recommendation for Use
- Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
- Evidence Dossier
- Therapeutic Advances in Oncology
- Drug Information Center Highlights of FDA Activities – 8/1/19
- WCLC Entrectinib ROS1
- Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple
- 2019 Precision Oncology Drug Approvals
- Novel Targeted Drugs Approved by the NMPA and FDA in 2019
- Breast Cancer (Recurrent Or Metastatic) Treatment Regimens
- A ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors a C Kyriakos P
- Advancing Health Through Innovation: New Drug Approvals 2019
- Rozlytrek, INN-Entrectinib)
- Oncology Agents Policy #: Rx.01.67
- Tumour-Agnostic Therapies
- Cases of ROS1-Rearranged Lung Cancer: When to Use Crizotinib, Entrectinib, Lorlatinib, and Beyond?
- Roche Media Template En
- Precision Medicine in Oncology: a Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
- Entrectinib) Capsules, for Oral Use • Hepatotoxicity: Monitor Liver Tests, Including ALT and AST, Every 2 Initial U.S
- Multidisciplinary Consensus on Optimising the Detection of NTRK Gene Alterations in Tumours
- Rozlytrek™ (Entrectinib) (Oral) Document Number: IC-0491 Last Review Date: 07/01/2021 Date of Origin: 09/09/2019 Dates Reviewed: 09/2019, 07/2020, 07/2021
- MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions Hiroki Sato1,2, Adam J
- Chugai to In-License ROS1/TRK Inhibitor Entrectinib
- Entrectinib Resistance Mechanisms in ROS1-Rearranged Non-Small Cell Lung Cancer
- An Oncology Mouthful: Updates and Pearls for Oral Oncolytics
- Introduction Conclusions Methods: Study Design
- ENTRECTINIB BRIEFING DOCUMENT Meeting Date
- Entrectinib for Treating NTRK Fusion-Positive Solid Tumours
- Roche to Present New Data from Its Broad Oncology Portfolio at The
- Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers Miho J
- Avapritinib in Unresectable Or Metastatic PDGFRA D842V-Mutant Gastrointestinal Stromal Tumours: Long- Term Efficacy and Safety Data from the NAVIGATOR Phase I Trial
- Prior Authorization Criteria
- Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
- Hazardous Medication Precautions: Personal Protective Equipment (Ppe)
- Update on Molecular Genetics of Gastrointestinal Stromal Tumors
- Tropomyosin Receptor Kinase Inhibitors in the Management Of
- Human Medicines Highlights Newsletter’ and Then Click on ‘Subscribe to This Feed’
- Tyrosine Kinase Receptors in Oncology